keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasys

keyword
https://www.readbyqxmd.com/read/28214371/the-risk-of-depression-suicidal-ideation-and-suicide-attempt-in-patients-with-psoriasis-psoriatic-arthritis-or-ankylosing-spondylitis
#1
J J Wu, R B Penfold, P Primatesta, T K Fox, C Stewart, S P Reddy, A Egeberg, J Liu, G Simon
BACKGROUND: Sparse information is available concerning mental health issues in psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS) patients. OBJECTIVE: To estimate risk of depression, suicidal ideation, and suicide attempt in patients with psoriasis, PsA, and AS, respectively, compared with the general population. METHODS: This population-based cohort study analyzed 36,214 psoriasis patients, 5,138 PsA patients, and 1,878 AS patients who were frequency-matched with a general population cohort...
February 18, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28214326/treatment-preferences-for-biologicals-in-psoriasis-experienced-patients-appreciate-sustainability
#2
Christian Kromer, Wiebke K Peitsch, Raphael Herr, Astrid Schmieder, Diana Sonntag, Marthe-Lisa Schaarschmidt
BACKGROUND AND OBJECTIVES: Treatment satisfaction can be improved by integrating patients' preferences into shared decision-making. We recently investigated patients' preferences for attributes of biologicals, and showed high preferences for safety and efficacy. The objective of the present study was to assess the impact of treatment experience on these preferences. PATIENTS AND METHODS: Preferences for outcome (probability of 50 % and 90 % improvement, time until response, sustainability of success, probability of mild and severe adverse events, probability of ACR 20 response) and process attributes (treatment location, frequency, duration, and delivery method) were analyzed in 200 participants with moderate-to-severe psoriasis using conjoint analysis...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28214324/behandlungspr%C3%A3-ferenzen-f%C3%A3-r-biologika-bei-psoriasis-erfahrene-patienten-legen-wert-auf-nachhaltigkeit
#3
Christian Kromer, Wiebke K Peitsch, Raphael Herr, Astrid Schmieder, Diana Sonntag, Marthe-Lisa Schaarschmidt
HINTERGRUND UND ZIELE: Die Therapiezufriedenheit kann durch die Berücksichtigung von Patientenpräferenzen in der gemeinsamen Entscheidungsfindung verbessert werden. Kürzlich untersuchten wir Patientenpräferenzen für Eigenschaften von Biologika und fanden starke Präferenzen für Sicherheit und Wirksamkeit. Die vorliegende Studie hatte das Ziel, Auswirkungen von Therapieerfahrung auf diese Präferenzen zu erheben. PATIENTEN UND METHODEN: Präferenzen für Ergebnis- (Wahrscheinlichkeit einer 50%igen und 90%igen Verbesserung, Zeit bis zum Ansprechen, Nachhaltigkeit des Erfolgs, Wahrscheinlichkeit von leichten und schweren Nebenwirkungen und Wahrscheinlichkeit eines ACR-20-Ansprechens) und Prozesseigenschaften (Behandlungsort, Behandlungshäufigkeit, Zeitaufwand und Applikationsweise) wurden bei 200 Teilnehmern mit mittelschwerer bis schwerer Psoriasis mit Hilfe von Conjoint-Analyse ermittelt...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28214311/-evergreen-psoriasis-neues-zu-genetik-therapie-und-%C3%A3-berhaupt
#4
EDITORIAL
Wolf-Henning Boehncke
No abstract text is available yet for this article.
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28214309/wirksamkeit-und-sicherheit-von-fumars%C3%A3-ureestern-in-kombination-mit-phototherapie-bei-patienten-mit-moderater-bis-schwerer-plaque-psoriasis-fast
#5
Peter Weisenseel, Kristian Reich, Wiebke Griemberg, Katharina Merten, Christine Gröschel, Natalie Nunez Gomez, Kirsi Taipale, Beate Bräu, Ina Zschocke
HINTERGRUND: Die Behandlung von Psoriasis-Patienten mit einer Kombination aus Fumarsäureestern (FSE, Fumaderm(®) ) und Phototherapie (UV) ist verbreitet, wurde aber im Rahmen von Studien wenig untersucht. Bisher liegen lediglich Daten aus einer kleinen Pilotstudie vor. Intention dieser Studie war, eine FSE/UV-Kombinationsbehandlung an einem größeren Patientenkollektiv mit mittelschwerer bis schwerer Psoriasis zu untersuchen. PATIENTEN UND METHODIK: In dieser prospektiven, multizentrischen, nichtinterventionellen Studie wurden Daten von Patienten mit FSE/UV-Kombinationstherapie hinsichtlich der Wirksamkeit (PGA' PASI, DLQI, EQ-5D), Sicherheit und Dosierung über einen Zeitraum von zwölf Monaten erfasst und mit Daten einer retrospektiven Studie mit FSE-Monotherapie verglichen...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28214304/efficacy-and-safety-of-fumaric-acid-esters-in-combination-with-phototherapy-in-patients-with-moderate-to-severe-plaque-psoriasis-fast
#6
Peter Weisenseel, Kristian Reich, Wiebke Griemberg, Katharina Merten, Christine Gröschel, Natalie Nunez Gomez, Kirsi Taipale, Beate Bräu, Ina Zschocke
BACKGROUND: While treatment of patients with moderate-to-severe psoriasis using a combination of fumaric acid esters (FAE, Fumaderm(®) ) and phototherapy (UV) is common practice, there have been hardly any studies investigating this regimen. Available information is limited to data from a small pilot study. The objective of the present study was to evaluate FAE/UV combination therapy in a larger patient cohort with moderate-to-severe psoriasis. PATIENTS AND METHODS: In this prospective noninterventional multicenter study, data from patients treated with FAE/UV combination therapy was assessed with regard to efficacy (PGA' PASI, DLQI, EQ-5D), safety, and dosage over a twelve-month period...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28214226/cd49a-expression-defines-tissue-resident-cd8-t-cells-poised-for-cytotoxic-function-in-human-skin
#7
Stanley Cheuk, Heinrich Schlums, Irène Gallais Sérézal, Elisa Martini, Samuel C Chiang, Nicole Marquardt, Anna Gibbs, Ebba Detlofsson, Andrea Introini, Marianne Forkel, Charlotte Höög, Annelie Tjernlund, Jakob Michaëlsson, Lasse Folkersen, Jenny Mjösberg, Lennart Blomqvist, Marcus Ehrström, Mona Ståhle, Yenan T Bryceson, Liv Eidsmo
Tissue-resident memory T (Trm) cells form a heterogeneous population that provides localized protection against pathogens. Here, we identify CD49a as a marker that differentiates CD8(+) Trm cells on a compartmental and functional basis. In human skin epithelia, CD8(+)CD49a(+) Trm cells produced interferon-γ, whereas CD8(+)CD49a(-) Trm cells produced interleukin-17 (IL-17). In addition, CD8(+)CD49a(+) Trm cells from healthy skin rapidly induced the expression of the effector molecules perforin and granzyme B when stimulated with IL-15, thereby promoting a strong cytotoxic response...
February 13, 2017: Immunity
https://www.readbyqxmd.com/read/28213896/filaggrin-loss-of-function-mutations-atopic-dermatitis-and-risk-of-actinic-keratosis-results-from-two-cross-sectional-studies
#8
Y M F Andersen, A Egeberg, E Balslev, C L T Jørgensen, P B Szecsi, S Stender, J Kaae, A Linneberg, G Gislason, L Skov, P M Elias, J P Thyssen
BACKGROUND: Common loss-of-function mutations in filaggrin gene (FLG) represent a strong genetic risk factor for atopic dermatitis (AD). Homozygous mutation carriers typically display ichthyosis vulgaris (IV) and many have concomitant AD. Previously, homozygous, but not heterozygous, filaggrin gene mutations have been associated with squamous cell carcinomas. OBJECTIVE: The first objective was to examine the association between FLG mutations and actinic keratosis (AK)...
February 18, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28213862/apremilast-a-review-in-psoriasis-and-psoriatic-arthritis
#9
Gillian M Keating
Apremilast (Otezla(®)) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplantar psoriasis. Most patient-reported outcomes, including pruritus and the total Dermatology Life Quality Index, also improved to a significantly greater extent with apremilast than with placebo, with significant improvements in pruritus and skin discomfort/pain visual analogue scale scores seen as early as week 2 with apremilast...
February 18, 2017: Drugs
https://www.readbyqxmd.com/read/28213804/psoriasis-and-cardiovascular-events-updating-the-evidence
#10
Line Raaby, Ole Ahlehoff, Annette de Thurah
So far, systematic reviews have suggested an increased risk of cardiovascular diseases (CVD) in psoriatic patients, though some results have been conflicting. The aim of this study was to update the current level of evidence through a systematic search in MEDLINE, EMBASE and Cochrane Central Register databases. In total, 13 high-quality observational studies estimating the incidence of CVD were included. Patients with mild psoriasis had an increased risk of stroke [Hazard ratio (HR) = 1.10, 95% CI: 1.0-1...
February 17, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28212864/gpr43-activation-enhances-psoriasis-like-inflammation-through-epidermal-upregulation-of-il-6-and-dual-oxidase-2-signaling-in-a-murine-model
#11
Ahmed Nadeem, Sheikh F Ahmad, Naif O Al-Harbi, Ahmed M El-Sherbeeny, Mohammed M Al-Harbi, Talal S Almukhlafi
The gut is densely inhabited by commensal bacteria, which metabolize dietary fibers/undigested carbohydrates and produce short-chain fatty acids such as acetate. GPR43 is one of the receptors to sense short-chain fatty acids, and expressed in various immune and non-immune cells. Acetate/GPR43 signaling has been shown to affect various inflammatory diseases through Th17 responses and NADPH oxidase (NOX)-derived reactive oxygen species (ROS) generation. However, no study has previously explored the effects of GPR43 activation during psoriasis-like inflammation...
February 14, 2017: Cellular Signalling
https://www.readbyqxmd.com/read/28212760/psoriasis-and-comorbid-diseases-implications-for-management
#12
REVIEW
Junko Takeshita, Sungat Grewal, Sinéad M Langan, Nehal N Mehta, Alexis Ogdie, Abby S Van Voorhees, Joel M Gelfand
As summarized in the first article in this continuing medical education series, the currently available epidemiologic data suggest that psoriasis may be a risk factor for cardiometabolic disease. Emerging data also suggest associations between psoriasis and other comorbidities beyond psoriatic arthritis, including chronic kidney disease, inflammatory bowel disease, hepatic disease, certain malignancies, infections, and mood disorders. Recognizing the comorbid disease burden of psoriasis is essential for ensuring comprehensive care of patients with psoriasis...
March 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28212759/psoriasis-and-comorbid-diseases-epidemiology
#13
REVIEW
Junko Takeshita, Sungat Grewal, Sinéad M Langan, Nehal N Mehta, Alexis Ogdie, Abby S Van Voorhees, Joel M Gelfand
Psoriasis is a common chronic inflammatory disease of the skin that is increasingly being recognized as a systemic inflammatory disorder. Psoriatic arthritis is a well-known comorbidity of psoriasis. A rapidly expanding body of literature in various populations and settings supports additional associations between psoriasis and cardiometabolic diseases, gastrointestinal diseases, kidney disease, malignancy, infection, and mood disorders. The pathogenesis of comorbid disease in patients with psoriasis remains unknown; however, shared inflammatory pathways, cellular mediators, genetic susceptibility, and common risk factors are hypothesized to be contributing elements...
March 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28211598/coronary-blood-flow-and-psoriasis
#14
Massimo Fioranelli, Maria Grazia Roccia, Torello Lotti
No abstract text is available yet for this article.
February 17, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28211161/psoriasis-and-psoriasiform-eruptions-in-pediatric-patients-with-inflammatory-bowel-disease-treated-with-anti-tumor-necrosis-factor-alpha-agents
#15
Joshua B Eickstaedt, Luke Killpack, Jeanne Tung, Dawn Davis, Jennifer L Hand, Megha M Tollefson
BACKGROUND: Anti-tumor necrosis factor alpha (TNF-α) agents are used to treat a variety of autoimmune and inflammatory conditions, including psoriasis. Paradoxically, numerous reports have documented new-onset or exacerbation of psoriasis or psoriasiform skin lesions (PSO) in patients treated with these agents for conditions other than PSO-particularly in adults with inflammatory bowel disease (IBD). Not much is known regarding similar cases in children. METHODS: A retrospective chart review was performed on children younger than 19 years of age with IBD seen at the Mayo Clinic between 2003 and 2015 who developed new-onset or recurrent PSO while undergoing anti-TNF-α therapy...
February 17, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28210825/recovery-of-nail-dystrophy-potential-new-therapeutic-indication-of-tofacitinib
#16
REVIEW
Jose A Jaller, Juan J Jaller, Antonio M Jaller, Juan J Jaller-Char, Sineida Berbert Ferreira, Rachel Ferreira, Morton Scheinberg
Nail dystrophy is a heterogeneous skin condition and in some subtypes, is associated with autoimmune diseases in particular psoriasis and psoriatic arthritis. In this report, we show that tofacitinib, a novel therapy for rheumatoid arthritis, appears to be beneficial in patients with nail disease refractory to other conventional modes of therapy.
February 16, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28209630/inhibition-of-phosphodiesterase-4-pde4-reduces-dermal-fibrosis-by-interfering-with-the-release-of-interleukin-6-from-m2-macrophages
#17
Christiane Maier, Andreas Ramming, Christina Bergmann, Rita Weinkam, Nicolai Kittan, Georg Schett, Jörg H W Distler, Christian Beyer
OBJECTIVES: To investigate the disease-modifying effects of phosphodiesterase 4 (PDE4) inhibition in preclinical models of systemic sclerosis (SSc). METHODS: We studied the effects of PDE4 inhibition in a prevention and a treatment model of bleomycin-induced skin fibrosis, in the topoisomerase mouse model as well as in a model of sclerodermatous chronic graft-versus-host disease. To better understand the mode of action of PDE4 blockade in preclinical models of SSc, we investigated fibrosis-relevant mediators in fibroblasts and macrophages from healthy individuals and patients suffering from diffuse-cutaneous SSc on blockade of PDE4...
February 16, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28209293/corrigendum-to-il-10-producing-regulatory-b-cells-are-decreased-in-patients-with-psoriasis-j-dermatol-sci-81-2016-93-100
#18
Mitsuha Hayashi, Koichi Yanaba, Yoshinori Umezawa, Yuki Yoshihara, Sota Kikuchi, Yozo Ishiuji, Hidehisa Saeki, Hidemi Nakagawa
No abstract text is available yet for this article.
February 10, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28207934/role-of-hla-c-06-in-clinical-response-to-ustekinumab-evidence-from-real-life-in-a-large-cohort-of-european-patients
#19
M Talamonti, M Galluzzo, J M van den Reek, E M de Jong, J L W Lambert, P Malagoli, L Bianchi, A Costanzo
BACKGROUND: Little is known about role of HLA-C*06 related to response to psoriasis treatments. OBJECTIVES: This study that involved four European centres aims to confirm the role of HLA-C*06 in a new large cohort of patients, as a pharmacogenetic marker of response to ustekinumab. METHODS: In this retrospective multicenter study we reviewed data of 255 psoriasis patients genotyped for HLA-C*06, which have started ustekinumab treatment between January 2014 and March 2015...
February 16, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28206666/high-expression-of-fas-cd95-on-cd4-circulating-t-cells-an-exclusion-criterion-in-the-diagnosis-of-mycosis-fungoides
#20
Aurélie Du-Thanh, Anne Serre-Cousiné, Pierre Portalès, Céline Girard, Bernard Guillot, Olivier Dereure
The aim of this 10-year monocentric prospective study was to determine a cut-off value of Fas/CD95 expression by peripheral blood CD4+ T lymphocytes in discriminating patients with mycosis fungoides from controls with cutaneous benign lymphocytic conditions. CD95 expression in peripheral blood CD4+ T lymphocytes was measured using flow cytometry in 330 patients referred for diagnosis: 104 with mycosis fungoides and 226 with eczema, psoriasis, drug reaction, etc. The sensitivity and specificity of different thresholds of CD95 expression were calculated regarding the final diagnosis of patients with mycosis fungoides or controls...
February 16, 2017: Acta Dermato-venereologica
keyword
keyword
43199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"